ACM
XFOR icon

Altium Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Altium Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,820
Closed -$4.26M – 157
2021
Q3 		$4.26M Buy
+26,820
New +$4.41M 1.12% 36

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Altium Capital Management's XFOR Position: Q4 2021 in Review

Altium Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2021, closing a stake of 26,820 shares — an estimated $4.26M sold.

Altium Capital Management first reported a position in XFOR in Q3 2021 and held it in 1 quarter. The position peaked at $4.26M in Q3 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2021.

  • Altium Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 26,820 X4 Pharmaceuticals shares in Q4 2021, an estimated $4.26M.
  • Altium Capital Management first reported a position in X4 Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Altium Capital Management's X4 Pharmaceuticals position peaked at $4.26M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.